Atea Pharmaceuticals Highlights 2026 Priorities, HCV Phase 3 Results Expected

Atea Pharmaceuticals will present its 2026 strategic priorities at the 44th Annual J.P. Morgan Healthcare Conference. The company is on track to announce Phase 3 topline results for its potential best-in-class regimen for treating HCV in 2026. Topline results from the C-BEYOND trial in North America are expected mid-year, while results from the C-FORWARD trial outside North America are expected year-end. Atea is also initiating a Phase 1 clinical program for its product candidate AT-587, expected mid-year.